Lifecore Biomedical Analyst Ratings
Lifecore Biomedical Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/01/2023 | 14.07% | Stephens & Co. | $8 → $9 | Maintains | Equal-Weight |
| 06/02/2023 | 39.42% | Barrington Research | $10 → $11 | Maintains | Outperform |
| 05/24/2023 | 26.74% | Barrington Research | $8 → $10 | Maintains | Outperform |
| 03/21/2023 | 1.39% | Barrington Research | $10 → $8 | Maintains | Outperform |
| 03/20/2023 | 1.39% | Barrington Research | $10 → $8 | Maintains | Outperform |
| 03/20/2023 | -74.65% | Stephens & Co. | $11 → $2 | Downgrades | Overweight → Equal-Weight |
| 03/17/2023 | 39.42% | Stephens & Co. | → $11 | Reiterates | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 09/01/2023 | 14.07% | 斯蒂芬斯公司 | $8→$9 | 维护 | 等重 |
| 06/02/2023 | 39.42% | 巴灵顿研究公司 | $10→$11 | 维护 | 跑赢大盘 |
| 2023年05月24日 | 26.74% | 巴灵顿研究公司 | $8→$10 | 维护 | 跑赢大盘 |
| 03/21/2023 | 1.39% | 巴灵顿研究公司 | $10→$8 | 维护 | 跑赢大盘 |
| 03/20/2023 | 1.39% | 巴灵顿研究公司 | $10→$8 | 维护 | 跑赢大盘 |
| 03/20/2023 | -74.65% | 斯蒂芬斯公司 | $11→$2 | 评级下调 | 超重→等重 |
| 03/17/2023 | 39.42% | 斯蒂芬斯公司 | →$11 | 重申 | →超重 |
What is the target price for Lifecore Biomedical (LFCR)?
Lifecore Biomedical(LFCR)的目标价格是多少？
The latest price target for Lifecore Biomedical (NASDAQ: LFCR) was reported by Stephens & Co. on September 1, 2023. The analyst firm set a price target for $9.00 expecting LFCR to rise to within 12 months (a possible 14.07% upside). 7 analyst firms have reported ratings in the last year.
斯蒂芬斯公司于2023年9月1日报道了Lifecore Biomedical(纳斯达克代码：LFCR)的最新目标价。这家分析公司将目标价定为9.00美元，预计LFCR将在12个月内上涨至14.07%。去年有7家分析公司公布了评级。
What is the most recent analyst rating for Lifecore Biomedical (LFCR)?
Lifecore Biomedical(LFCR)的最新分析师评级是多少？
The latest analyst rating for Lifecore Biomedical (NASDAQ: LFCR) was provided by Stephens & Co., and Lifecore Biomedical maintained their equal-weight rating.
斯蒂芬斯公司提供了对Lifecore Biomedical(纳斯达克代码：LFCR)的最新分析师评级，Lifecore Biomedical维持其同等权重的评级。
When is the next analyst rating going to be posted or updated for Lifecore Biomedical (LFCR)?
Lifecore Biomedical(LFCR)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lifecore Biomedical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lifecore Biomedical was filed on September 1, 2023 so you should expect the next rating to be made available sometime around September 1, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Lifecore Biomedical的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Lifecore Biomedical的上一次评级是在2023年9月1日提交的，所以你应该预计下一次评级将在2024年9月1日左右的某个时候提供。
Is the Analyst Rating Lifecore Biomedical (LFCR) correct?
分析师对Lifecore Biomedical(LFCR)的评级正确吗？
While ratings are subjective and will change, the latest Lifecore Biomedical (LFCR) rating was a maintained with a price target of $8.00 to $9.00. The current price Lifecore Biomedical (LFCR) is trading at is $7.89, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Lifecore Biomedical(LFCR)评级维持不变，目标价在8.00美元至9.00美元之间。Lifecore Biomedical(LFCR)目前的交易价格为7.89美元，超出了分析师的预测区间。
译文内容由第三方软件翻译。